Short answer
Compass Therapeutics, Inc. (CMPX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers quarterly and six-month financial results ended June 30, 2026.
Compass Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers quarterly and six-month financial results ended June 30, 2026
- Exhibit 99.1 contains the detailed results and management commentary for investor review
Item EX-99.1 · Exhibit EX-99.1
- Tovecimig ORR reached 18.0% versus 5.3% for paclitaxel, with p-value improving to 0.0228, supporting potential BLA filing later this year
- FDA feedback expected in Q3 2026, while full tovecimig data receive an oral ESMO presentation in October
- CTX-8371 cohort expansions enrolling in triple-negative breast cancer, non-small cell lung cancer and Hodgkin lymphoma, with data expected in Q4
- Cash and marketable securities $180 million at June 30, 2026, with management projecting operational funding into 2028
- Quarterly net loss $25.2 million, R&D expenses $19.6 million and G&A expenses $7.4 million, reflecting rising clinical and pre-commercialization investment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Compass Therapeutics, Inc. 8-K filings
Get the next CMPX 8-K as it lands
Follow CMPX for push alerts, or ask the research agent what this filing means.